National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Urethral Cancer Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 01/09/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Anterior Urethral Cancer






Posterior Urethral Cancer






Urethral Cancer Associated With Invasive Bladder Cancer






Recurrent Urethral Cancer






Get More Information From NCI






Changes to This Summary (01/09/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Recurrent Urethral Cancer

Current Clinical Trials

Standard treatment options for female/male recurrent urethral cancer:

  1. Locally recurrent urethral cancer after radiation therapy should be treated by surgical excision.
  2. Locally recurrent urethral cancer after surgery alone should be considered for combination radiation and wider surgical resection.[1]

Treatment options under clinical evaluation:

  • Metastatic urethral cancer should be considered for clinical trials using chemotherapy. Early evidence suggests that transitional cell cancer of the urethra may respond favorably to the same chemotherapy regimens employed for advanced transitional cell cancer of the bladder.
Current Clinical Trials

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent urethral cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site.

References

  1. Scher HI, Yagoda A, Herr HW, et al.: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. J Urol 139 (3): 475-7, 1988.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov